Literature DB >> 25556777

Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis.

Stefano F Rimoldi1, Franz H Messerli, Patricia Chavez, Giulio G Stefanini, Urs Scherrer.   

Abstract

Although recent guidelines recommend the combination of calcium channel blockers (CCBs) and thiazide (-like) diuretics, this combination is not widely used in clinical practice. The aim of this meta-analysis was to assess the efficacy and safety of this combination regarding the following endpoints: all-cause and cardiovascular mortality, myocardial infarction, and stroke. Four studies with a total of 30,791 of patients met the inclusion criteria. The combination CCB/thiazide (-like) diuretic was associated with a significant risk reduction for myocardial infarction (risk ratio [RR], 0.83; 95% confidence interval [CI], 0.73-0.95) and stroke (RR, 0.77; CI, 0.64-0.92) compared with other combinations, whereas it was similarly effective compared with other combinations in reducing the risk of all-cause (RR, 0.89; CI, 0.75-1.06) and cardiovascular (RR, 0.89; CI 0.71-1.10) mortality. Elderly patients with isolated systolic hypertension may particularly benefit from such a combination, since both drug classes have been shown to confer cerebrovascular protection. ©2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25556777      PMCID: PMC8031913          DOI: 10.1111/jch.12462

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  41 in total

1.  Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.

Authors:  Bryan Williams; Peter S Lacy; Simon M Thom; Kennedy Cruickshank; Alice Stanton; David Collier; Alun D Hughes; H Thurston; Michael O'Rourke
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

2.  Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study.

Authors:  Pierre Boutouyrie; Anne Isabelle Tropeano; Roland Asmar; Isabelle Gautier; Athanase Benetos; Patrick Lacolley; Stéphane Laurent
Journal:  Hypertension       Date:  2002-01       Impact factor: 10.190

3.  The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients.

Authors:  Lisheng Liu; Yuqing Zhang; Guozhang Liu; Wei Li; Xuezhong Zhang; Alberto Zanchetti
Journal:  J Hypertens       Date:  2005-12       Impact factor: 4.844

4.  The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.

Authors:  Stevo Julius; Michael A Weber; Sverre E Kjeldsen; Gordon T McInnes; Alberto Zanchetti; Hans R Brunner; John Laragh; M Anthony Schork; Tsushung A Hua; John Amerena; Ivan Balazovjech; Graham Cassel; Bela Herczeg; Nevres Koylan; Dieter Magometschnigg; Silja Majahalme; Felipe Martinez; Willie Oigman; Ricardo Seabra Gomes; Jun-ren Zhu
Journal:  Hypertension       Date:  2006-07-24       Impact factor: 10.190

Review 5.  Secondary arterial hypertension: when, who, and how to screen?

Authors:  Stefano F Rimoldi; Urs Scherrer; Franz H Messerli
Journal:  Eur Heart J       Date:  2013-12-23       Impact factor: 29.983

6.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

Review 7.  Salt sensitivity of Japanese from the viewpoint of gene polymorphism.

Authors:  Tomohiro Katsuya; Kazuhiko Ishikawa; Ken Sugimoto; Hiromi Rakugi; Toshio Ogihara
Journal:  Hypertens Res       Date:  2003-07       Impact factor: 3.872

8.  Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.

Authors:  Roland E Schmieder; Sverre E Kjeldsen; Stevo Julius; Gordon T McInnes; Alberto Zanchetti; Tsushung A Hua
Journal:  J Hypertens       Date:  2008-03       Impact factor: 4.844

Review 9.  Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis.

Authors:  Alastair J S Webb; Urs Fischer; Ziyah Mehta; Peter M Rothwell
Journal:  Lancet       Date:  2010-03-13       Impact factor: 79.321

Review 10.  Importance of potassium in cardiovascular disease.

Authors:  D A Sica; A D Struthers; W C Cushman; M Wood; J S Banas; M Epstein
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 May-Jun       Impact factor: 3.738

View more
  6 in total

1.  Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and policy implications.

Authors:  Donald J DiPette; Jamario Skeete; Emily Ridley; Norm R C Campbell; Patricio Lopez-Jaramillo; Sandeep P Kishore; Marc G Jaffe; Antonio Coca; Raymond R Townsend; Pedro Ordunez
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-11-27       Impact factor: 3.738

2.  Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis.

Authors:  Stefano F Rimoldi; Franz H Messerli; Patricia Chavez; Giulio G Stefanini; Urs Scherrer
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-01-05       Impact factor: 3.738

3.  Effects of calcium channel blocker benidipine-based combination therapy on target blood pressure control and cardiovascular outcome: a sub-analysis of the COPE trial.

Authors:  Seiji Umemoto; Toshio Ogihara; Masunori Matsuzaki; Hiromi Rakugi; Yasuo Ohashi; Takao Saruta
Journal:  Hypertens Res       Date:  2016-12-01       Impact factor: 3.872

4.  S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.

Authors:  Sang-Ho Jo; Sung-Ji Park; Eung Ju Kim; Soo-Joong Kim; Hyun-Jae Cho; Jong-Min Song; Jinho Shin; Jin Joo Park; Joon-Han Shin; Kyoo-Rok Han; Dong-Ju Choi
Journal:  Trials       Date:  2018-06-20       Impact factor: 2.279

5.  Neutrophil to Lymphocyte Ratio Predicts Adverse Cardiovascular Outcome in Peritoneal Dialysis Patients Younger than 60 Years Old.

Authors:  Yingsi Zeng; Zijun Chen; Qinkai Chen; Xiaojiang Zhan; Haibo Long; Fenfen Peng; Fengping Zhang; Xiaoran Feng; Qian Zhou; Lingling Liu; Xuan Peng; Guanhua Guo; Yujing Zhang; Zebin Wang; Yueqiang Wen; Jiao Li; Jianbo Liang
Journal:  Mediators Inflamm       Date:  2020-05-20       Impact factor: 4.711

6.  Blood pressure-lowering efficacy of indapamide SR/amlodipine combination in older patients with hypertension: A post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria).

Authors:  Olivier Hanon; Laure Caillard; Edouard Chaussade; Intza Hernandorena; Clemence Boully
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-07-18       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.